• Home
  • Search Results

Search Results

374 studies match your search
Open

This study tests whether CT-155 improves negative symptoms associated with schizophrenia.

Do you have a diagnosis of Schizophrenia? Are you interested in improving the negative symptoms (lack of pleasure, social withdrawal, lack of motivation) associated with schizophrenia? If so, you may be eligible to participate in a research study to find out if a new device "CT-155" improves negative symptoms. Compensation provided.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Behavior
  • Chronic Conditions
  • Mental and Emotional Health
Open

Dupilumab for Eosinophilic Esophagitis with Severe Strictures (DESTRICT Study)

Are you 16 years and older, have Eosinophilic Esophagitis, have tried other therapies but they have not worked, and you have had multiple dilations for narrowing in your throat in the past 12 months? If you meet these criteria then you may be eligible for a study investigating the use of dupilumab to treat EoE patients with severe strictures. Compensation provided.

Age & Gender
  • 16 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Stomach, Digestion and Gut Health
  • Ear, Nose, and Throat
Open

IMGN853-0420: Multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers following 1 prior line of platinum-based chemotherapy

Do you have cancer that has come back after your first round of treatment and your tumor has tested positive for folate receptor-alpha (FRα)? A new study drug called mirvetuximab soravtansine (MIRV) is being studied as a possible treatment for your type of cancer

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Uterine (endometrial), Ovarian)
Open

Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions

Have you been diagnosed with a precancerous breast condition that places you at "high risk" for breast cancer? If so, you may be able to take part in a research study looking at giving a new study drug ruxolitinib as a potential drug to prevent breast cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Open

Study of sacituzumab govitecan with or without pembrolizumab in Metastatic TNBC

Have you been diagnosed with triple negative breast cancer? If so, you may be able to take part in a research study looking at the safety of giving a new drug called Sacituzumab Govitecan with or without a drug called Pembrolizumab to patients with PDL-1-negative metastatic triple negative breast cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Open

SAMURAI Study- Stereotactic radiation therapy with immune therapy for patients with Renal Cell Cancer

Do you have renal cell cancer that has spread beyond your kidney and surgery is not recommended? You may be able to take part in a research study to help us learn if adding radiation therapy to your usual cancer treatment may help your cancer shrink.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Kidney)
Open

Physical Activity in College-Age Native American Adults

Are you affiliated with a federal and/or state-recognized tribe and between the ages of 18-25? We want to learn about physical activity practices in the college-age Native American Community. Take our 30-minute survey answering questions about your environment, how your culture promotes physical activity, your access to physical activity, and what you do for physical activity.

Age & Gender
  • 18 years ~ 25 years
  • Male, Female, Gender Inclusive
Study Interest
  • Healthy Volunteer or General Population
  • Minority Health
Visit Location
100% Remote (online, phone, text)
Open

Stereotactic radiosurgery with DDR inhibitor (Olaparib) followed by adjuvant durvalumab and chemothe

Have you been diagnosed with breast cancer with brain metastases? If so, you may be able to take part in a research study looking at the safety of giving a new drug called olaparib concurrently (at the same time) with stereotactic radiosurgery to patients with breast cancer with brain metastases.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Brain and Other Nervous System, Breast)
Open

Post-Surgical Stereotactic Radiotherapy v Surgically Targeted Radiation w Gamma Tile for Brain Mets

Have you been diagnosed with metastatic brain cancer (tumor)? If so, you may be able to take part in a research study looking at the safety of giving radiation therapy through a device called GammaTiles™ to patients with newly diagnosed metastatic brain tumors planned for surgical resection.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Brain, Head, Nervous System
  • Cancer (Brain and Other Nervous System)
Open

Study for Blood Cancer

Have you been diagnosed with Leukemia? You may be able to take part in a research study to find out if a new study drug can help put your blood cancer into remission.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research